Currently, there are ongoing trials recruiting patients evaluating the use of mTOR inhibitors (i.e., mTORC1/2 inhibitor AZD2014 or the oral AKT inhibitor AZD5363 for recurrent endometrial, NCT02208375; ovarian cancer and a phase I trial of the combination of AZD2014 and weekly paclitaxel, NCT02193633) and in view of this new data, this question might be clarified. Here, AKT1 is linked to ovarian cancer.